Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
Wall Street Journal - April 21, 2007
The agency raised its concerns ahead of a meeting of an outside panel of medical experts that will meet Tuesday to make recommendations about a Pfizer Inc. drug called maraviroc, a new type of drug known as a CCR5 co-receptor antagonist. Unlike current HIV drugs on the market that are designed to treat the virus, maraviroc is designed to block a receptor on cells known as CCR5 to keep HIV from infecting healthy cells.
The FDA said other CCR5 drugs that were being developed have shown an increased risk of safety problems. Pfizer said its studies showed the drug had no significant effect on the heart, and no raised incidence of liver problems, cancer or infection compared with treatment with other HIV drugs.
070421
WJ070405
Copyright © 2007 - The Wall Street Journal. Reproduction of this article (other than one copy for personal reference) must be cleared through the WSJ Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .